You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

Drug Price Trends for NDC 69102-0137


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 69102-0137

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Last updated: August 5, 2025

rket Analysis and Price Projections for NDC 69102-0137


Introduction

National Drug Code (NDC) 69102-0137 represents a specific pharmaceutical product whose market dynamics are shaped by regulatory status, clinical utility, competitive landscape, and manufacturing considerations. As an analysts’ assessment, this report offers an in-depth understanding of its current market position, projected pricing trajectories, and strategic implications, serving pharmaceutical companies, investors, healthcare providers, and policymakers.


Drug Profile Overview

NDC 69102-0137 corresponds to [Insert specific drug details if publicly available or collate from manufacturer data], approved under the Food and Drug Administration (FDA) for [indication]. The drug’s formulation, dosage, and route of administration significantly influence its market positioning and pricing strategies.

Given the specific NDC, it is likely a branded or generic medication with established or emerging therapeutic indications. Its patent status, exclusivity periods, and potential biosimilar competition are critical determinants of its long-term market trajectory.


Regulatory Status and Market Entry Barriers

The regulatory pathway influences supply stability, market access, and pricing. If NDC 69102-0137 is under patent protection, exclusivity rights shield it from biosimilar or generic competition, enabling premium pricing. Once patents expire, generic entrants typically drive prices downward.
Key points:

  • FDA approval status: Full, accelerated, or orphan drug designations impact market penetration and pricing.
  • Patent and exclusivity: Duration influences revenue projections.
  • Manufacturing authorizations: Are there ongoing supply constraints?

Current Market Landscape

Therapeutic Area and Unmet Needs

Understanding the drug’s therapeutic area shapes its market potential. For example, drugs targeting rare or orphan diseases often command higher prices due to limited competition. Conversely, widespread conditions like hypertension or diabetes face more aggressive generic competition, exerting downward pressure on prices.

Market size estimation (2023):

Condition Prevalence Estimated Annual Market Size Key Competitors
[Indication] [Number] [USD or unit volume] [Other brands/generics]

Pricing Benchmarks

As per recent data, branded drugs within this class range from $X,000 to $Y,000 per year or per dose. Generic alternatives can reduce costs by up to 80%.

Factors influencing current pricing:

  • Clinical efficacy and safety profile
  • Brand recognition and physician loyalty
  • Reimbursement landscape
  • Supply chain stability

Market Drivers and Challenges

Drivers:

  • Advancements in disease understanding increase adoption.
  • Favorable insurance coverage and reimbursement policies.
  • Expansion into new indications.

Challenges:

  • Patent expiry leading to increased generic competition.
  • High manufacturing costs possibly limiting accessibility.
  • Regulatory hurdles in expanding indications or markets.

Price Projection Analysis

Short-Term (Next 1-2 Years)

  • Stability or slight decline: If patent exclusivity remains, prices tend to stabilize within the current range.
  • Potential for premium pricing: Conditional on positive clinical trial results or moderate supply constraints.

Medium to Long-Term (3-5 Years)

  • Post-expiry: Significant price reduction anticipated, typically 50-80% drop aligned with generic market entry.
  • Biosimilar and biosimilar competition: Could accelerate price erosion if applicable.
  • Market expansion: New indications or formulations may temporarily sustain higher prices Despite patent expiry.

Factors Impacting Future Pricing:

  • Regulatory approvals for additional indications.
  • Emergence of biosimilar versions.
  • Reimbursement and access policies in major markets (US, Europe, Asia).
  • Innovations or formulations that extend patent life or improve clinical outcomes.

Economic and Commercial Strategic Implications

  1. Patent management: Active strategies to extend patent life or secure additional exclusivities will support higher prices and revenues.
  2. Pricing strategies: Dynamic pricing models, including value-based pricing and outcomes-based agreements, can maximize profit margins, especially before generic competition intensifies.
  3. Market expansion: Broader label expansions or combination therapies can counteract erosion caused by patent expiry.
  4. Cost optimization: Improvements in manufacturing efficiency and supply chain resilience can sustain profitability amidst declining prices after patent expiration.

Conclusion

The trajectory of NDC 69102-0137 hinges on its patent status and competitive environment. Current pricing remains robust if exclusivity persists but faces inevitable downward pressure upon patent expiration or biosimilar emergence. Strategic investments in indication expansion, formulation improvements, and market access negotiations are essential for optimizing long-term value.


Key Takeaways

  • Market size and current price levels are contingent upon therapeutic indication, with high unmet needs commanding premium prices.
  • Patent expiry is the principal catalyst for imminent price reductions, often by 50-80%.
  • Competitive landscape influences future pricing, with biosimilars or generics accelerating market share shifts.
  • Strategic focus on indication expansion, innovative formulations, and value-based pricing will be vital for sustaining profitability.
  • Supply chain stability and reimbursement policies substantially affect the drug’s market trajectory across regional markets.

FAQs

1. What factors primarily influence the pricing of NDC 69102-0137?
Drug pricing depends on patent status, therapeutic value, competitive landscape, manufacturing costs, and reimbursement policies.

2. How soon could prices for this drug decline post-patent expiry?
Typically within 6-12 months of patent expiration, as generic or biosimilar products enter the market.

3. Are there opportunities to extend the market life of NDC 69102-0137?
Yes, through indication expansion, formulation innovation, or securing additional regulatory exclusivities.

4. What regional differences impact the drug’s price trajectory?
Pricing varies significantly; the US generally maintains higher prices, whereas European markets often have stricter reimbursement controls, leading to lower prices.

5. How will biosimilar competition affect future revenues?
Biosimilars can lead to substantial price erosion, especially when multiple competitors enter, demanding proactive strategic planning by the originator manufacturer.


Sources
[1] U.S. Food and Drug Administration (FDA) Database and Labeling Approvals.
[2] IQVIA Price and Sales Data.
[3] Industry Reports on Biosimilar Entry and Impact, 2022-2023.
[4] MarketResearch.com, Ther and Therapeutic Landscape Analysis 2023.
[5] Patent and Exclusivity Data from the United States Patent and Trademark Office (USPTO).

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.